Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 8/20 | 0.39 |
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026058 | 0.92 | PBRM1 (0.36) | BAZ2BHSD17B1MAPK14GRM5 | |
| SCHEMBL1026129 | 0.86 | PBRM1 (0.36) | BAZ2BRXRARXRBRXRGHSD17B1 | |
| SCHEMBL1027481 | 0.83 | HSD17B1 (0.43) | BAZ2BMAOAMAOBPRKCIMEN1 | |
| SCHEMBL1026571 | 0.75 | AHCY (0.39) | MEN1KMT2ANPSR1 | |
| SCHEMBL12721179 | 0.73 | MEN1 (0.40) | BAZ2BMAOAMAOBPRKCIMEN1 | |
| SCHEMBL1275258 | 0.73 | MEN1 (0.55) | BAZ2BMAOAMAOBPRKCIMEN1 | |
| SCHEMBL1028605 | 0.72 | ACACB (0.35) | MEN1MAPK1KMT2AGRM5 | |
| SCHEMBL1027112 | 0.72 | DPP9 (0.36) | — | |
| SCHEMBL1027483 | 0.71 | KDM4E (0.43) | BAZ2BMAPK1KMT2AHSD17B1 | |
| SCHEMBL10102252 | 0.71 | MAOA (0.53) | BAZ2BMAOAMAOBPRKCIMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | BAZ2B 2650/4885MAOA 1427/4885MAOB 1057/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | BAZ2B 3366/4885MAOA 984/4885MAOB 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.